LEP and Alzheimer disease: For example, administration of leptin decreases AD-like pathology in transgenic mouse models of AD pathology (TgCRND8 and Tg2576) [35], [37], with increased AD risk in human patients reported for subjects with low levels of circulating leptin [38].